The problem of cardiac safety of nonsteroidal anti-inflammatory drugs-Reference-Cited by-同舟云学术

The problem of cardiac safety of nonsteroidal anti-inflammatory drugs

Published:2016 Issue:5 Volume:88 Page:113
ISSN:0040-3660
Container-title:Terapevticheskii arkhiv
language:en
Short-container-title:Ter. arkh.

Author:

Shostak N. A.,Klimenko A. A.,Demidova N. A.,Kondrashov A. A.

Publisher

LLC Obyedinennaya Redaktsiya

Subject

General Medicine,Endocrinology, Diabetes and Metabolism,History,Family Practice

Reference41 articles.

1. Intercontinental Marketing Services (IMS) Health, II Mercato Farmaceutico 2001-2002.

2. Singh G, Miller JD, Huse DM, Pettitt D, D'Agostino RB, Russell MW. Consequences of increased systolic blood pressure in patients with osteoarthrosis and rheumatoid arthritis. J Rheumat. 2003;30(4):714-719.

3. Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. Emerging therapeutic strategies on osteoarthritis patients with hypertension. EULAR Sattellite symposium: Optimising the management of osteoarthritis: emerging therapies. Br Med J. 2010;27.

4. Wolfe F, Zhao S, Pettitt D. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. J Rheumatol. 2004;31(6):1143-1151.

5. Harris RC, Breyer MD. Update on Cyclooxygenase-2 Inhibitors. Clin J Am Soc Nephrol. 2006;1(2):236-245.

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Meloxicam clinical effects;Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova;2022

2. Meloxicam in pain syndrome treatment of comorbid diseases patients;Meditsinskiy sovet = Medical Council;2021-12-01